The pso Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the pso Hub cannot guarantee the accuracy of translated content. The pso and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The PsOPsA Hub is supported by educational grants. All educational content is developed independently by SES in collaboration with our expert steering committee, with no input or influence from financial supporters. We would like to express our gratitude to the following companies for their support: • UCB: For website development, launch, and ongoing maintenance. • UCB: For educational content and news updates.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View pso content recommended for you
FDA accepts supplemental new drug application for roflumilast foam 0.3% in scalp and body psoriasis
On September 24, 2024, the U.S. Food and Drug Administration (FDA) accepted a supplemental new drug application for roflumilast foam 0.3% to treat scalp and body psoriasis in individuals aged ≥12 years.1 This decision is based on the positive results from the ARRECTOR (NCT05028582) trial.
Roflumilast cream 0.3% is already approved in patients aged ≥6 years with plaque psoriasis.
ARRECTOR trial1
ARRECTOR is an ongoing, double-blind, vehicle-controlled phase III trial investigating the safety and efficacy of roflumilast foam 0.3% in patients with scalp and body psoriasis. The primary endpoints are achieving Scalp-Investigator Global Assessment (S-IGA) and Body-Investigator Global Assessment (B-IGA).
Key data
Overall, 432 patients aged ≥12 years with body and scalp plaque psoriasis were included.
At Week 8:
- S-IGA was achieved in 66.4% vs 27.8% of patients in the roflumilast vs vehicle groups, respectively (p < 0.0001).
- B-IGA was achieved in 45.5% vs 20.1% of patients in the roflumilast vs vehicle groups, respectively (p < 0.0001).
The most commonly reported adverse reactions in ≥1% of patients were headache (3.1%), diarrhea (2.5%), nausea (1.7%), and nasopharyngitis (1.3%).
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content